These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36055978)

  • 21. Serotonin transporter genomic biomarker for quantitative assessment of ondansetron treatment response in alcoholics.
    Seneviratne C; Johnson BA
    Front Psychiatry; 2012; 3():23. PubMed ID: 22470354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ondansetron reduces mood disturbance among biologically predisposed, alcohol-dependent individuals.
    Johnson BA; Ait-Daoud N; Ma JZ; Wang Y
    Alcohol Clin Exp Res; 2003 Nov; 27(11):1773-9. PubMed ID: 14634493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ondansetron reduces the craving of biologically predisposed alcoholics.
    Johnson BA; Roache JD; Ait-Daoud N; Zanca NA; Velazquez M
    Psychopharmacology (Berl); 2002 Apr; 160(4):408-13. PubMed ID: 11919668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence.
    Sellers EM; Toneatto T; Romach MK; Somer GR; Sobell LC; Sobell MB
    Alcohol Clin Exp Res; 1994 Aug; 18(4):879-85. PubMed ID: 7978099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective randomized pharmacogenetic study of topiramate for treating alcohol use disorder.
    Kranzler HR; Morris PE; Pond T; Crist RC; Kampman KM; Hartwell EE; Lynch KG
    Neuropsychopharmacology; 2021 Jul; 46(8):1407-1413. PubMed ID: 33568796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective, open-label trial of ondansetron in adolescents with alcohol dependence.
    Dawes MA; Johnson BA; Ait-Daoud N; Ma JZ; Cornelius JR
    Addict Behav; 2005 Jul; 30(6):1077-85. PubMed ID: 15925118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety.
    Falk DE; Ryan ML; Fertig JB; Devine EG; Cruz R; Brown ES; Burns H; Salloum IM; Newport DJ; Mendelson J; Galloway G; Kampman K; Brooks C; Green AI; Brunette MF; Rosenthal RN; Dunn KE; Strain EC; Ray L; Shoptaw S; Ait-Daoud Tiouririne N; Gunderson EW; Ransom J; Scott C; Leggio L; Caras S; Mason BJ; Litten RZ;
    Alcohol Clin Exp Res; 2019 Jan; 43(1):158-169. PubMed ID: 30403402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial.
    Müller C; Pongratz S; Pidlich J; Penner E; Kaider A; Schemper M; Raderer M; Scheithauer W; Ferenci P
    Eur J Gastroenterol Hepatol; 1998 Oct; 10(10):865-70. PubMed ID: 9831410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pilot study of full-dose ondansetron to treat heavy-drinking men withdrawing from alcohol in Brazil.
    Corrêa Filho JM; Baltieri DA
    Addict Behav; 2013 Apr; 38(4):2044-51. PubMed ID: 23396176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of serotonergic treatment efficacy using age of onset and Type A/B typologies of alcoholism.
    Roache JD; Wang Y; Ait-Daoud N; Johnson BA
    Alcohol Clin Exp Res; 2008 Aug; 32(8):1502-12. PubMed ID: 18565156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study.
    Salloum IM; Cornelius JR; Daley DC; Kirisci L; Himmelhoch JM; Thase ME
    Arch Gen Psychiatry; 2005 Jan; 62(1):37-45. PubMed ID: 15630071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serotonin transporter and receptor genes significantly impact nicotine dependence through genetic interactions in both European American and African American smokers.
    Yang Z; Seneviratne C; Wang S; Ma JZ; Payne TJ; Wang J; Li MD
    Drug Alcohol Depend; 2013 May; 129(3):217-25. PubMed ID: 23290502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence.
    Johnson BA; Roache JD; Ait-Daoud N; Javors MA; Harrison JM; Elkashef A; Mojsiak J; Li SH; Bloch DA
    Drug Alcohol Depend; 2006 Oct; 84(3):256-63. PubMed ID: 16631323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, double-blind, placebo-controlled proof-of-concept study of ondansetron for bipolar and related disorders and alcohol use disorder.
    Sherwood Brown E; McArdle M; Palka J; Bice C; Ivleva E; Nakamura A; McNutt M; Patel Z; Holmes T; Tipton S
    Eur Neuropsychopharmacol; 2021 Feb; 43():92-101. PubMed ID: 33402258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence.
    Johnson BA; Ait-Daoud N; Elkashef AM; Smith EV; Kahn R; Vocci F; Li SH; Bloch DA;
    Int J Neuropsychopharmacol; 2008 Feb; 11(1):1-14. PubMed ID: 17470315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial.
    Anton RF; Latham P; Voronin K; Book S; Hoffman M; Prisciandaro J; Bristol E
    JAMA Intern Med; 2020 May; 180(5):728-736. PubMed ID: 32150232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence.
    Wong CJ; Witcher J; Mallinckrodt C; Dean RA; Anton RF; Chen Y; Fijal BA; Ouyang H; Dharia S; Sundseth SS; Schuh KJ; Kinon BJ
    Alcohol Clin Exp Res; 2014 Feb; 38(2):511-20. PubMed ID: 24010675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prazosin and cyproheptadine in combination in the treatment of alcohol use disorder: A randomized, double-blind, placebo-controlled trial.
    Aubin HJ; Berlin I; Guiraud J; Bruhwyler J; Batel P; Perney P; Trojak B; Bendimerad P; Guillou M; Bisch M; Grall-Bronnec M; Labarrière D; Delsart D; Questel F; Moirand R; Bernard P; Trovero F; Pham HP; Tassin JP; Puech A
    Addiction; 2024 Jul; 119(7):1211-1223. PubMed ID: 38597214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study.
    Kranzler HR; Pierucci-Lagha A; Feinn R; Hernandez-Avila C
    Alcohol Clin Exp Res; 2003 Jul; 27(7):1150-5. PubMed ID: 12878921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.